Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Santoni-Rugiu

Showing results (31-40 of 94) with videos related to

Pageof 10
Sort By:
International Journal of Cancer|July 28, 2011
Expression of C4.4A in precursor lesions of pulmonary adenocarcinoma and squamous cell carcinomaBenedikte Jacobsen, Eric Santoni-Rugiu, Martin Illemann, et al.
JCO Precision Oncology|July 7, 2022
Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic <i>ANK3-RET</i> Fusion in <i>EGFR</i>-Mutated Non-Small-Cell Lung CancerEdyta M Urbanska, Jens B Sørensen, Linea C Melchior, et al.
The Journal of Molecular Diagnostics : JMD|June 11, 2014
Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesotheliomaMorten Andersen, Morten Grauslund, Jesper Ravn, et al.
Clinical Lung Cancer|July 12, 2020
Intracranial Response of ALK<sup>+</sup> Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic RadiosurgeryEdyta Maria Urbanska, Eric Santoni-Rugiu, Linea Cecilie Melchior, et al.
Ugeskrift for Laeger|January 23, 2026
[Smoking-related interstitial lung diseases]Akam Dler Colnadar, Milan Mohammad, Peter Kjeldgaard, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|July 22, 2014
Personalized oncology: genomic screening in phase 1Ida Viller Tuxen, Lars Jønson, Eric Santoni-Rugiu, et al.
Oncogene|September 13, 2002
E2F activity is essential for survival of Myc-overexpressing human cancer cellsEric Santoni-Rugiu, Dominique Duro, Thomas Farkas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2011
Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survivalZarah Glad Zimling, Jens Benn Sørensen, Thomas Alexander Gerds, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|March 30, 2026
Correlation of TP53 Mutations With p53 Expression and Ki-67 Index in Pulmonary Large Cell Neuroendocrine CarcinomasMartin Stampe, Jonas Smidt, Linea Melchior, et al.
Lung Cancer (Amsterdam, Netherlands)|November 8, 2017
Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutationEric Santoni-Rugiu, Morten Grauslund, Linea C Melchior, et al.
Pageof 10

Showing results (31-40 of 94) with videos related to

Sort By:
Pageof 10
International Journal of Cancer|July 28, 2011
Expression of C4.4A in precursor lesions of pulmonary adenocarcinoma and squamous cell carcinomaBenedikte Jacobsen, Eric Santoni-Rugiu, Martin Illemann, et al.
JCO Precision Oncology|July 7, 2022
Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic <i>ANK3-RET</i> Fusion in <i>EGFR</i>-Mutated Non-Small-Cell Lung CancerEdyta M Urbanska, Jens B Sørensen, Linea C Melchior, et al.
The Journal of Molecular Diagnostics : JMD|June 11, 2014
Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesotheliomaMorten Andersen, Morten Grauslund, Jesper Ravn, et al.
Clinical Lung Cancer|July 12, 2020
Intracranial Response of ALK<sup>+</sup> Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic RadiosurgeryEdyta Maria Urbanska, Eric Santoni-Rugiu, Linea Cecilie Melchior, et al.
Ugeskrift for Laeger|January 23, 2026
[Smoking-related interstitial lung diseases]Akam Dler Colnadar, Milan Mohammad, Peter Kjeldgaard, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|July 22, 2014
Personalized oncology: genomic screening in phase 1Ida Viller Tuxen, Lars Jønson, Eric Santoni-Rugiu, et al.
Oncogene|September 13, 2002
E2F activity is essential for survival of Myc-overexpressing human cancer cellsEric Santoni-Rugiu, Dominique Duro, Thomas Farkas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2011
Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survivalZarah Glad Zimling, Jens Benn Sørensen, Thomas Alexander Gerds, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|March 30, 2026
Correlation of TP53 Mutations With p53 Expression and Ki-67 Index in Pulmonary Large Cell Neuroendocrine CarcinomasMartin Stampe, Jonas Smidt, Linea Melchior, et al.
Lung Cancer (Amsterdam, Netherlands)|November 8, 2017
Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutationEric Santoni-Rugiu, Morten Grauslund, Linea C Melchior, et al.
Pageof 10